

14th Nottingham Upper GI Endoscopy & Barrett's Course

1st to 3rd July 2026

Albert Hall Conference Centre, Nottingham

DAY 1 – WEDNESDAY 1ST JULY 2026

8:00-8:50 Registration & Coffee

8:50-9:00 Welcome & Introductions

9:00-9:45 SPONSORED UPPER GI ENDOSCOPY IMAGE & VIDEO QUIZ

Presenter: Jacobo Ortiz

Full Faculty Panel Commenting on

9:45-10:40 QUALITY IN UPPER GI ENDOSCOPY – GET THE FOUNDATIONS RIGHT I

Chairs: **Alfredo Lucendo & Guiomar Moral**

9:45-10:00 Current UGI KPIs are not fit for purpose – Lessons learned from PROSPERO and ideas for a change. **Leo Alexandre**

10:00-10:15 The rationale behind the need for dedicated lists and dedicated endoscopists – The cold real world outside large tertiary university teaching hospitals.

Elizabeth Ratcliffe

10:15-10:30 Adequate sedation and impact on high-quality endoscopy - Shifting the UK mindset to align with global standards. **Srisha Hebbar**

10:30-10:40 Q&A and Quiz Prize Winner

10:40-11:10 COFFEE BREAK & NETWORKING

11:10-12:05 QUALITY IN UPPER GI ENDOSCOPY – GET THE FOUNDATIONS RIGHT II

Chairs: **Maria Valeria Matteo & Keith Siau**

11:10-11:25 How to take biopsies in the Upper GI tract – Optimal biopsy technique. **Julia Gauci**

11:25-11:40 Photo documentation and structured reporting in Upper GI Endoscopy – Why is so relevant? **Yuto Shimamura**

11:40-11:55 Eosinophilic Oesophagitis (EoE): Still an overlooked condition – Optimizing endoscopic recognition and biopsy strategy in a patchy disease. **Alfredo Lucendo**

11:55-12:05 Q&A

**12:05-13:05 BACK TO BASICS – HOW TO IMPROVE MY OPTICAL DIAGNOSTIC SKILLS.
INTERACTIVE IMAGE & VIDEO SESSIONS**

Chairs: **Julia Gauci & Yuto Shimamura**

12:05-12:20 How to identify, assess and describe early Barrett's neoplasia: Impact on treatment decision making. **Wouter Nagengast**

12:20-12:35 How to identify, assess and describe early oesophageal squamous neoplasia: Impact on treatment decision making. **Alana Ebigbo**

12:35-12:50 How to identify, assess and describe early gastric: Impact on treatment decision making. **Mário Dinis-Ribeiro**

12:50-13:05 Q&A

13:05-14:00 LUNCH BREAK & NETWORKING

14:00-16:00 BENIGN UPPER GI CONDITIONS

Chairs: **Elizabeth Ratcliffe & Krish Ragunath**

14:00-14:15 The mishmash - Non-Neoplastic Lesions of the Upper GI Tract. Diagnosis, assessment, and management: Ignore, biopsy or resect? **Keith Siau**

14:15-14:30 Acute Upper GI Bleeding: From scope to solution – Risk stratification and the latest evidence on mechanical, thermal, injection and topical therapies for Non-Variceal bleeding. **Mo Abdelrahim**

14:30-14:45 Functional Lumen Imaging Probe (FLIP) Panometry - The Dallas Consensus and how to standardize pre-POEM diagnostic algorithms and post-treatment follow up protocols. **Vani Konda**

14:45-14:55 Q&A

Chairs: **Alanna Ebigbo & Nastazja Pilonis**

14:55-15:10 The concerns around long term use of PPI and the magnitude of risk. Are still indications for maintenance treatment or we should go for symptom control only for all?

Leo Alexandre

15:10-15:25 Maintenance therapy in EoE: What, who, when, and how much? Should we always aim for histological remission? **Alfredo Lucendo**

15:25-15:40 Medical and endoscopy treatment options for GAVE. Is there an evidence-based protocol to follow? **Keith Siau**

15:40-15:50 Q&A

15:50-16:15 TEA BREAK & NETWORKING

16:15-17:30 NEW ADVANCES IN UPPER GI INTERVENTIONAL ENDOSCOPY

Chairs: James Catton & Mo Abdelrahim

16:15-16:30 Treatment options and strategies to manage recurrent Upper GI neoplasia after previous endoscopy treatment...and when to give up. **Henna Söderström**

16:30-16:45 Regenerative Endoscopy: Science Fiction or Clinical Reality? - Where Are We Now, Where Are We Going, and What Is the Evidence. **Maria Valeria Matteo**

16:45-17:00 Anti-reflux endoscopic treatments – Options available, patient selection, long term symptom relief and how they compare with the established surgical approach. **Yuto Shimamura**

17:00-17:15 Endoluminal Vacuum Therapy (EVT) - Current options, case selection, standardization and outcomes. **Roos Pouw**

17:15-17:30 Q&A

17:30-19:00 AQUILANT/3D MATRIX NETWORKING EVENING DRINKS & SNACKS

From trainee to expert: Navigating advanced Interventional Upper GI Endoscopy training – Insights from those who were just there not that long ago

Roundtable interactive discussion: **Julia Gauci, Maria Valeria Matteo & Mo Abdelrahim**

DAY 2 – THURSDAY 2ND JULY 2026

8:30-9:00 Welcome back & Coffee

9:00-10:00 Journal Club - Critical reading of recent key publications

This interactive session will take a deep dive into a selection of recent high-impact studies shaping the diagnosis, surveillance, and treatment of Barrett's oesophagus and early neoplasia. Through critical appraisal and group discussion, we will examine each study's design, methodology, strengths, limitations, and clinical relevance. These studies challenge well established clinical practices, and we aim to assess whether their findings can be effectively translated into meaningful, evidence-based changes in patient care.

Chair: **Massi di Pietro**

9:00-9:15 Biomarker risk stratification to make surveillance work: Deconstructing the NHS Pilot and DELTA Trial. **Nastazja Pilonis**

Description:

This talk will critically examine recent advances in population-level screening for Barrett's oesophagus analysing the results of the recently published prospective study evaluating risk stratification with data from both the NHS pilot programme and the DELTA trial. We will explore the rationale, design, and outcomes of these key initiatives, highlighting lessons learned and the practical implications for early detection of oesophageal adenocarcinoma. Topics will include emerging screening tools, risk stratification models, and real-world feasibility within a public healthcare system. The session aims to provide a data-driven perspective on whether widespread screening for Barrett's is ready for prime time—and what comes next.

9:15-9:30 Endoscopy surveillance for Barrett's Oesophagus under the spotlight: Deconstructing the BOSS Trial. **Helen Coleman**

Description:

This session will delve into the long-awaited results of the BOSS trial, the largest randomized controlled study evaluating the impact of endoscopic surveillance in Barrett's oesophagus. We will critically assess the trial design, key findings, and their implications for clinical practice, particularly considering the balance between cancer detection, patient outcomes, and resource utilization. The talk will also explore how BOSS fits within the broader landscape of Barrett's management strategies and whether it reshapes our approach to surveillance in routine care.

9:30-9:45 Endoscopic treatment for high-Risk T1a and T1b Adenocarcinoma: Deconstructing the CONGRESS Trial. **Roos Pouw**

Description:

This lecture will explore the findings and clinical implications of the CONGRESS trial, focusing on the role of endoscopic therapy in managing high-risk T1a and T1b oesophageal adenocarcinoma. We will dissect the trial's methodology, patient selection

criteria, and outcomes, and compare them with current practice and guidelines. Particular attention will be given to oncological safety, risk stratification, and the evolving role of endoscopic resection in cases traditionally considered for surgery. The session aims to offer a nuanced, evidence-based perspective on managing early neoplastic disease in the oesophagus.

9:45-10:00 Q&A

10:00-10:30 COFFEE BREAK & NETWORKING

10:30-11:15 Barrett's Surveillance Debate: Abandon or Evolve?

Chair: **Helen Coleman**

10:30-10:45 End surveillance now: The evidence says enough. **Massi di Pietro**

10:45-11:00 Switch It Up: Making surveillance work with non-endoscopy tools. **Vani Konda**

11:00-11:15 Discussion

11:15-12:15 UPPER GI THERAPEUTIC ENDOSCOPY. PRACTICAL IMAGE&VIDEO SESSION

Chair: **Wouter Nagengast & Henna Söderström**

11:15-11:30 How to perform an Oesophageal EMR. Tips & Tricks and how to avoid mistakes. **Nastazja Pilonis**

11:30-11:45 Principles and strategies on how to perform an Upper GI ESD. Tips & Tricks and how to avoid mistakes. **Mo Abdelrahim**

11:45-12:00 Decoding EMR/ESD histopathology reports: A guide for endoscopists. **Sindhu Menon**

12:00-12:15 Q&A

12:15-13:00 Barrett's Treatment Debate: Should ESD Replace EMR for Early Neoplasia resection?

Chair: **Roos Pouw**

12:15-12:30 Yes - Go Big or Go Home: Why ESD should replace EMR. **Alanna Ebigbo**

12:30-12:45 No - EMR Endures: proven, practical, and here to stay. **Julia Gauci**

12:45-13:00 Discussion

13:00-14:00 LUNCH BREAK & NETWORKING

14:00-15:15 SOME OF THE CURRENT CONTROVERSIES IN BARRETT'S ENDOTHERAPY

Chair: **Vani Konda & Mário Dinis-Ribeiro**

14:00-14:15 The risk of overtreatment in Barrett's Endotherapy: Often less is more – Knowing when to hold back may be the best clinical decision. **Wouter Nagengast**

14:15-14:30 Low Grade Dysplasia (LGD) in the real world beyond the SURF Trial: True Dysplasia or Overdiagnosis? Ablation or Follow up? **Massi di Pietro**

14:30-14:45 Pushing the boundaries: endoscopic management of pT1b adenocarcinoma - Is there still a role for surgery? **Henna Söderström**

14:45-15:00 NICE Guidelines recommend considering radiotherapy with/without chemotherapy for high risk T1b oesophageal adenocarcinoma after EMR/ESD – Supporting evidence and current real-world practice. **Eleanor James**

15:00-15:15 Q&A

15:15-16:00 Barrett's Post-Endotherapy Follow-Up Debate: Is It Time to Discharge Patients after more 15+ years generating evidence?

Chair: **Leo Alexandre**

15:15-15:30 Yes - Time to let go: Discharge after proven success. And I'll tell you when. **Mário Dinis-Ribeiro**

15:30-15:45 No - Don't drop the guard: Follow-up should continue. And I'll tell you how. **Elizabeth Ratcliffe**

15:45-16:00 Discussion

16:00-16:30 TEA BREAK & NETWORKING

16:30-17:30 UGI MDT PANEL REAL CASE DISCUSSIONS

UGI MDT Chair – **James Catton**

UGI MDT Panel – **Mário Dinis-Ribeiro, Yutaro Higashi, Eleanor James, Sindhu Menon, Massi di Pietro, Yuto Shimamura and Henna Söderström,**

DAY 3 – FRIDAY 3RD JULY 2026

9:00-9:30 Welcome back & Coffee

9:30-11:30 HANDS-ON SESSION – GROUP A

Mo Abdelrahim, Leo Alexandre, Alanna Ebigbo, Julia Gauci, Maria Valeria Matteo, Guiomar Moral, Wouter Nagengast, Yuto Shimamura and Henna Söderström

9:30-11:30 INTERACTIVE PRACTICAL SESSIONS – GROUP B

9:30-10:30 Interactive Real Case Discussions

Mário Dinis-Ribeiro, Vani Konda, Alfredo Lucendo, Jacobo Ortiz, Massi di Pietro, Nataszja Pilonis, Roos Pouw, Krish Ragunath, Elizabeth Ratcliffe and Keith Siau

10:30-11:30 How to set up a Barrett's service: The Nottingham Experience

- How all began: The history of the Nottingham Barrett's Unit – **Krish Ragunath**
- Nurse Led Barrett's Clinic – **Anuj Abraham**
- Early Upper GI Neoplasia (EUGIN) Nurse Specialist Role – **Anu Jose**
- Nurse led Capsule Sponge Service – **Louise Warburton**

11:30-12:00 COFFEE BREAK & NETWORKING

12:00-14:00 HANDS-ON SESSION – GROUP B

Mo Abdelrahim, Leo Alexandre, Alanna Ebigbo, Julia Gauci, Maria Valeria Matteo, Guiomar Moral, Wouter Nagengast, Yuto Shimamura and Henna Söderström

12:00-14:00 INTERACTIVE PRACTICAL SESSIONS – GROUP A

12:00-13:00 Interactive Real Case Discussions

Mário Dinis-Ribeiro, Vani Konda, Alfredo Lucendo, Jacobo Ortiz, Massi di Pietro, Nataszja Pilonis, Roos Pouw, Krish Ragunath, Elizabeth Ratcliffe and Keith Siau

13:00-14:00 How to set up a Barrett's service: The Nottingham Experience

- How all began: The history of the Nottingham Barrett's Unit – **Krish Ragunath**
- Nurse Led Barrett's Clinic – **Anuj Abraham**
- Early Upper GI Neoplasia (EUGIN) Nurse Specialist Role – **Anu Jose**
- Nurse led Capsule Sponge Service – **Louise Warburton**

14:00-14:30 GRAB YOUR LUNCH, THANK YOU AND GOOD BYE

COURSE FACULTY

Mo Abdelrahim, Sheffield Teaching Hospitals, Sheffield, UK

Leo Alexandre, Norfolk and Norwich NHS Trust , Norwich, UK

James Catton, Nottingham University Hospitals NHS Trust, Nottingham, UK

Helen Coleman, Queen's University Belfast, Belfast, UK

Mário Dinis-Ribeiro, Porto Comprehensive Cancer Center, Porto, Portugal

Alanna Ebigbo, Katholisches Klinikum Bochum, Bochum, Germany

Julia Gauci, NHS Lothian, Edinburgh, UK

Srisha Hebbar, University Hospitals of North Midlands, Stoke-on-Trent, UK

Yutaro Higashi, Nottingham University Hospitals NHS Trust, Nottingham, UK

Eleanor James, Nottingham University Hospitals NHS Trust, Nottingham, UK

Vani Konda, Baylor University Medical Center, Dallas, USA

Alfredo Lucendo, Hospital General de Tomelloso, Tomelloso, Spain

Maria Valeria Matteo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Sindhu Menon, Nottingham University Hospitals, Nottingham, UK

Guionor Moral, Nottingham University Hospitals, Nottingham, UK

Wouter Nagengast, University Medical Center Groningen, Groningen, The Netherlands

Jacobo Ortiz, Nottingham University Hospitals Nottingham, UK

Massi di Pietro, Cambridge University Hospitals and University of Cambridge, Cambridge, UK

Nataszja Pilonis, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Roos Pouw, Utrecht Medical Centre, Utrecht, The Netherlands

Krish Ragunath, Royal Perth Hospital and Curtin University, Perth, Australia

Elizabeth Ratcliffe, Northern Care Alliance NHS Foundation Trust, Rochdale, UK

Yuto Shimamura, Austin Health and University of Melbourne, Melbourne, Australia

Keith Siau, Royal Cornwall Hospitals NHS Trust, Truro, UK

Henna Söderström, Helsinki University Central Hospital, Helsinki, Finland